When a new cancer treatment is approved based on a clinical trial, the next step is seeing how it performs in the real world.
New research presented at the ASCO 2026 Annual Meeting provides encouraging news for people with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer. The study found that mirvetuximab soravtansine (Elahere®) delivered similar benefits in everyday clinical practice as it did in the landmark MIRASOL clinical trial that led to its approval.
These findings offer reassurance that the treatment’s benefits extend beyond the carefully selected patients who typically participate in clinical trials.
A recap of the MIRASOL trial
Mirvetuximab soravtansine is a targeted therapy designed to seek out and attack ovarian cancer cells that express folate receptor alpha (FRα).
In the phase III MIRASOL trial, the treatment significantly outperformed standard chemotherapy for patients with FRα-positive platinum-resistant ovarian cancer who had received one to three prior treatments.
Patients who received mirvetuximab soravtansine experienced:
- Longer progression-free survival (the length of time before the cancer grew or spread)
- Longer overall survival
- A manageable safety profile
These results helped establish mirvetuximab soravtansine as an important treatment option for eligible patients.
Why real-world studies matter
Clinical trials are essential for evaluating new treatments, but trial participants often represent a narrower group of patients than those seen in everyday oncology clinics.
In real life, patients may:
- Have received more prior treatments
- Have more complex medical histories
- Have cancers that behave differently than those included in clinical trials
- Be older or have additional health conditions
Because of this, researchers wanted to see whether mirvetuximab soravtansine would perform similarly outside of a clinical trial setting.
What did the researchers study?
The investigators analyzed electronic health record data from cancer centers across the United States.
The study included:
- 129 patients treated with mirvetuximab soravtansine
- 342 patients treated with standard single-agent chemotherapy, such as paclitaxel, topotecan, or doxorubicin
Notably, the real-world patient population was more diverse than the patients enrolled in MIRASOL. Some patients had received as many as 11 prior lines of therapy, and the study included patients whose cancers were particularly difficult to treat.
This makes the findings especially meaningful because they reflect the experiences of a broader range of patients seen in everyday practice.
Mirvetuximab continued to outperform chemotherapy
The study found that patients treated with mirvetuximab soravtansine experienced longer periods before their cancer progressed compared with those receiving chemotherapy. Importantly, these results closely matched what researchers observed in the MIRASOL clinical trial.
Even when researchers looked at a subgroup of patients whose characteristics more closely resembled the MIRASOL trial population, mirvetuximab soravtansine continued to show a similar advantage over chemotherapy.
Why this is encouraging
One of the most important takeaways from this study is that mirvetuximab soravtansine appeared to maintain its effectiveness even among patients who may have been considered too complex or heavily pretreated for a clinical trial.
This suggests that the benefits seen in MIRASOL are not limited to a highly selected patient population. For patients and families, that means there is growing confidence that the treatment can provide meaningful benefit in routine clinical practice, not just in a research setting.
Safety findings remained consistent
Researchers also evaluated side effects reported in real-world practice.
The study found no new safety concerns, and the side effects observed were consistent with what has been reported in previous clinical trials. This is reassuring because it suggests that physicians are able to successfully manage treatment-related side effects outside of a clinical trial environment.
As seen in previous studies, eye-related side effects remain an important consideration, which is why regular eye monitoring continues to be recommended for patients receiving mirvetuximab soravtansine.
What this means for patients
For patients facing platinum-resistant ovarian cancer, these findings provide encouraging confirmation that the improvements observed in clinical trials can translate into real-world care, even among patients with more complex treatment histories.
Looking for more information? Access trusted educational resources designed to help you navigate ovarian cancer treatment.
